본문 바로가기
HOME> 저널/프로시딩 > 저널/프로시딩 검색상세

저널/프로시딩 상세정보

권호별목차 / 소장처보기

H : 소장처정보

T : 목차정보

Seminars in nuclear medicine 9건

  1. [해외논문]   Letter from the Editors   SCI SCIE

    Blaufox, M. Donald , Freeman, Leonard M.
    Seminars in nuclear medicine v.48 no.1 ,pp. 1 - 1 , 2018 , 0001-2998 ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  2. [해외논문]   Guest Editorial   SCI SCIE

    Kostakoglu, Lale
    Seminars in nuclear medicine v.48 no.1 ,pp. 2 - 3 , 2018 , 0001-2998 ,

    초록

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  3. [해외논문]   PET/CT for Staging; Past, Present, and Future   SCI SCIE

    El-Galaly, Tarec Christoffer (Address reprint requests toDepartment of Hematology, Aalborg University Hospital, Moelleparkvej 4, DK-9000 Aalborg, Denmark.) , Gormsen, Lars Christian , Hutchings, Martin
    Seminars in nuclear medicine v.48 no.1 ,pp. 4 - 16 , 2018 , 0001-2998 ,

    초록

    Accurate and reproducible staging is crucial for management of malignant lymphomas. Disease stage influences treatment decisions more significantly than any other clinical information in most lymphoma subtypes, and contributes with important prognostic information on its own or as part of clinical prognostic scores. Information derived from medical imaging is the single most important determinant of disease stage, and the introduction PET/CT for lymphoma has led to substantial changes in the concept as well as practice of lymphoma staging. Over time, the most important change in lymphoma staging has been the abandonment of extensive pathologic staging intended in the original Ann Arbor classification. The 2014 Lugano Classification represents the most recent expert recommendation for staging of lymphoma. This revision recognizes the improved diagnostic accuracy of PET/CT over stand-alone CT and recommended PET/CT for routine staging of all FDG-avid lymphomas. Routine bone marrow biopsies are also discouraged in Hodgkin lymphoma as well as in selected cases of diffuse large B-cell lymphoma. The scope of this review is to give the reader insight into the history of staging, the purpose of lymphoma staging in the context of contemporary treatment strategies, and the advantages of PET/CT staging over conventional staging. We also discuss the controversies of PET/CT replacing conventional bone marrow biopsies in different lymphoma subtypes and summarize recommendations by the recent Lugano classification.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  4. [해외논문]   Interim FDG-PET Imaging in Lymphoma   SCI SCIE

    Gallamini, Andrea (Address reprint requests toA. Lacassagne Cancer Centre, 33, Rue de Valombrose, 16129 Nice, France.) , Zwarthoed, Colette
    Seminars in nuclear medicine v.48 no.1 ,pp. 17 - 27 , 2018 , 0001-2998 ,

    초록

    In the present article, the authors reviewed the rationale of FDG-PET/CT performed at an interim time point during therapy (iPET), focusing on the transition from standard, anatomical assessment of tumor shrinkage with CT to document a chemotherapy response, to the use of functional imaging with PET to assess chemosensitivity of the individual tumor. The prognostic or predictive role of iPET in different lymphoma subsets has been reviewed, with particular emphasis on early and advanced-stage Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, extranodal natural killer/T-cell lymphoma, and primary mediastinal B-cell lymphoma. A large body of evidence exists in most lymphoma subtypes stressing the role of iPET for early chemotherapy response during first-line chemotherapy treatment, but an increased number of reports have recently been published focusing on the role of iPET in relapsed or refractory lymphoma to predict treatment outcome. Varying patterns of FDG uptake was observed across various lymphoma entities; hence, interpretation of FDG-PET scans should be in the context of the tumor architecture and the prevalence of cellular population, in particular, neoplastic vs non-neoplastic inflammatory cells present in tissue microenvironment. In the second part of the article, the authors reviewed the iPET–response adapted clinical trials and the clinical benefits of this strategy compared to standard non–PET adapted therapy. In particular, the authors extrapolated the reproducibility of FDG-PET image interpretation and the feasibility of a timely treatment adaptation based on FDG-PET results in daily clinical practice. This is essential for the reader, as the iPET-adapted strategy has become the standard of care in both early- and advanced-stage Hodgkin lymphoma, and, in the future, probably this strategy will be expanded to primary mediastinal B-cell lymphoma, follicular lymphoma, and peripheral T-cell lymphoma.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  5. [해외논문]   PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma   SCI SCIE

    Kobe, Carsten (Address reprint requests toKlinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Köln, Kerpener Str. 62, 50937 Köln, Germany.) , Dietlein, Markus , Hellwig, Dirk
    Seminars in nuclear medicine v.48 no.1 ,pp. 28 - 36 , 2018 , 0001-2998 ,

    초록

    Over the course of many decades, combined chemotherapy and radiotherapy adapted to the stage of disease have become the optimal and standard treatment for Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma. Besides achieving optimized cure rates of the underlying disease, reduction of toxicity has become a major goal. Since the introduction of FDG-PET for the staging and restaging of patients with lymphoma, a high predictive value of F-18-FDG-PET in response assessment has been observed. Several PET-response-guided therapy regimens have already been established, and even more PET-adapted study designs are being tested in large study groups. PET has a very high negative predictive value following chemotherapy, and radiotherapy can be safely omitted in PET-negative patients with HL after effective chemotherapy with regimens such as bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in advanced stages. As “state-of-the-art” PET-guided therapy is based on the results of large clinical trials, the reliability of end-of-treatment PET as a basis for abandoning radiotherapy in early and intermediate HL stages remains to be shown. As in HL, the predictive value of FDG-PET after induction therapy of diffuse large B-cell lymphoma is higher than that of CT alone so that we obtain relevant prognostic information unavailable through anatomical imaging. Recent results from trials in aggressive non-HL with a de-escalating strategy suggest that radiotherapy may be safely omitted if FDG-PET is negative after standard chemoimmunotherapy. Since 2007, FDG-PET at end of treatment is integrated into the International Working Group criteria and became the imaging tool of choice for response assessment in aggressive lymphoma. Robust and reproducible interpretation criteria are being used both in the ongoing clinical trials and in daily routine. The recommended five-point scale has become the standard in PET response assessment, with the caveat that the consequence of a PET scan may be influenced by foregoing and following treatments.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  6. [해외논문]   PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up   SCI SCIE

    Karls, Shawn (Address reprint requests to Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Avenue, DL203, Boston, MA 02215.) , Shah, Hina , Jacene, Heather
    Seminars in nuclear medicine v.48 no.1 ,pp. 37 - 49 , 2018 , 0001-2998 ,

    초록

    FDG-PET/CT is an established first-line diagnostic imaging tool used in the staging of most lymphomas and for post-therapy response assessment in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL). Many of the subtypes of lymphoid neoplasms classified by the World Health Organization demonstrate significant FDG-avidity or uptake; however, many guidelines and Lugano classification do not recommend the use of FDG-PET/CT in assessing response to therapy for these non-HL, non-DLBCL subtypes as a first-line diagnostic tool. This article reviews the role of FDG-PET/CT in the evaluation of the other most common “FDG-avid” lymphomas than HL and DLBCL, the role of FDG-PET/CT before autologous stem cell transplant, and for post-treatment follow-up. Follicular lymphoma is most commonly FDG-avid with a wide range of uptake that generally correlates with the histologic grade, a major determinant of aggressiveness and prognosis. FDG-PET/CT is more sensitive and specific than CT for detecting residual disease post therapy for both aggressive and indolent follicular lymphoma. Post-treatment FDG-PET/CT for follicular lymphoma has significant prognostic value, that is, better predicts progression-free and overall survival than does conventional post-treatment assessment with CT. FDG-PET/CT is useful in the staging of mantle cell lymphoma, a very aggressive, incurable subtype of lymphoma; however, data show mixed results on the benefits of FDG-PET/CT over conventional CT assessment in post-therapy response evaluation. Peripheral T-cell lymphomas, a rare aggressive group of T-cell lymphomas, are often FDG-avid. Post-therapy FDG-PET/CT results have major prognostic value and therapeutic implications in many subtypes of peripheral T-cell lymphomas. Post-treatment FDG-PET/CT is superior to conventional CT for determining chemosensitivity of lymphoma, and therefore is better able to predict which patients will have a greater benefit or outcome with autologous stem cell transplant. There are mixed data on the value of FDG-PET/CT for surveillance after treatment because of high reported false-positive rates and accuracy that depends on the duration or timing of surveillance and the subtype of lymphoma.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  7. [해외논문]   Metabolic Tumor Volume Metrics in Lymphoma   SCI SCIE

    Kostakoglu, Lale (Address reprint requests to Lale Kostakoglu, MD, MPH, Nuclear Medicine and Molecular Imaging, Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box: 1141, New York, NY 10029.) , Chauvie, Sté , phane
    Seminars in nuclear medicine v.48 no.1 ,pp. 50 - 66 , 2018 , 0001-2998 ,

    초록

    Although visual assessment using the Deauville criteria is strongly recommended by guidelines for treatment response monitoring in all FDG-avid lymphoma histologies, the high rate of false-positives and concerns about interobserver variability have motivated the development of quantitative tools to facilitate objective measurement of tumor response in both routine and clinical trial settings. Imaging studies using functional quantitative measures play a significant role in profiling oncologic processes. These quantitative metrics allow for objective end points in multicenter clinical trials. However, the standardization of imaging procedures including image acquisition parameters, reconstruction and analytic measures, and validation of these methods are essential to enable an individualized treatment approach. A robust quality control program associated with the inclusion of proper scanner calibration, cross-calibration with dose calibrators and across other scanners is required for accurate quantitative measurements. In this section, we will review the technical and methodological considerations related to PET-derived quantitative metrics and the relevant published data to emphasize the potential value of these metrics in the prediction of patient prognosis in lymphoma.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  8. [해외논문]   PET/CT in Radiation Therapy Planning   SCI SCIE

    Specht, Lena (Address reprint requests to Lena Specht, MD, PhD, Department of Oncology, Rigshospitalet, University of Copenhagen, Section 3994, Blegdamsvej 9, 2100 Copenhagen, Denmark.) , Berthelsen, Anne Kiil
    Seminars in nuclear medicine v.48 no.1 ,pp. 67 - 75 , 2018 , 0001-2998 ,

    초록

    Radiation therapy (RT) is an important component of the management of lymphoma patients. Most lymphomas are metabolically active and accumulate 18 F-fluorodeoxyglucose (FDG). Positron emission tomography with computer tomography (PET/CT) imaging using FDG is used routinely in staging and treatment evaluation. FDG-PET/CT imaging is now also used routinely for contouring the target for RT, and has been shown to change the irradiated volume significantly compared with CT imaging alone. Modern advanced imaging techniques with image fusion and motion management in combination with modern highly conformal RT techniques have increased the precision of RT, and have made it possible to reduce dramatically the risks of long-term side effects of treatment while maintaining the high cure rates for these diseases.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지
  9. [해외논문]   PET/CT in Lymphoma: Current Overview and Future Directions   SCI SCIE

    Cheson, Bruce D. (Address reprint requests toGeorgetown University Hospital, 3800 Reservoir Rd, NW, Washington, DC 20007.)
    Seminars in nuclear medicine v.48 no.1 ,pp. 76 - 81 , 2018 , 0001-2998 ,

    초록

    Over the past several decades, PET has emerged as critical to accurate staging and restaging of lymphomas. Nonetheless, a number of critical issues regarding its optimal use remain. Whereas risk-adapted strategies appear to improve the outcome of patients with Hodgkin lymphoma, results are less convincing in non-Hodgkin lymphoma. Assessment of metabolic tumor volume before treatment may permit novel induction strategies. New drugs that may induce an immune response may result in a false-positive FDG/PET scan, mandating modifications of current criteria to consider tumor flare reactions. Application of PET may be improved by integration of biomarker studies and a better understanding of the role of the microenvironment. Methods to improve the integration of FDG/PET enhance its role in the management of patients with lymphoma, leading to improved patient outcome.

    원문보기

    원문보기
    무료다운로드 유료다운로드

    회원님의 원문열람 권한에 따라 열람이 불가능 할 수 있으며 권한이 없는 경우 해당 사이트의 정책에 따라 회원가입 및 유료구매가 필요할 수 있습니다.이동하는 사이트에서의 모든 정보이용은 NDSL과 무관합니다.

    NDSL에서는 해당 원문을 복사서비스하고 있습니다. 아래의 원문복사신청 또는 장바구니담기를 통하여 원문복사서비스 이용이 가능합니다.

    이미지

    Fig. 1 이미지

논문관련 이미지